Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills, and eventually affects the ability to carry out simple tasks. It is linked to the buildup of abnormal proteins, such as amyloid plaques and tau tangles, in the b...
Search Bar & Filters
Found 488 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of 18F-MFBG PET scans to assess heart nerve activity in people with Parkinsons disease PD, multiple system atrophy MSA, dementia with Lewy bodies DLB, and Alzheimers disease AD. The study compares this method with the current standard 123I-MIBG SPECT scans, focusing on distinguishing between PD and MSA as well as DLB and AD. This is a prospective study conducted at two centers, aiming to validate the accuracy and feasibility of 18F-MFBG PET for these neurological conditions. Participants will undergo several imaging tests including dynamic cardiac 18F-MFBG PET, 123I-MIBG SPECT, and cerebral 18F-PE2I PET scans. Healthy volunteers and patients with confirmed diagnoses will be included, with groups divided by age and disease duration. A dosimetry study will also be conducted for healthy volunteers to measure radiation exposure from 18F-MFBG. Multiple visits to the hospital are required for scans and assessments. During the study, participants will have thorough neurological assessments, brain MRI scans, and blood sampling alongside PET and SPECT imaging. Researchers will evaluate diagnostic accuracy, effect size of tracer uptake changes, and relationships between heart nerve imaging and brain dopamine transporter changes and autonomic dysfunction. The study includes monitoring for safety and will analyze regional heart uptake patterns. Participants can expect 3 to 4 hospital visits with detailed imaging and clinical evaluations over the study period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new radioactive tracer called 18FACI-19626 for its ability to detect pathological protein TDP-43 in the brain. This protein is involved in rare forms of dementia such as frontotemporal dementia FTD and amyotrophic lateral sclerosis ALS. The study also aims to assess the safety and tolerability of this tracer when injected into participants, including both healthy individuals and those with suspected TDP-43 accumulation. Participants will receive the 18FACI-19626 tracer intravenously followed by brain scans using positron emission tomography PET. The study includes up to 45 participants divided into groups including healthy controls and those with TDP-43 proteinopathies or related neurodegenerative diseases. Some participants may undergo a second PET scan within one month to evaluate the reliability of the tracers measurements. During the study, participants will attend two to three visits over about three months. These visits include eligibility screening with physical and neurological exams, questionnaires, blood and urine tests, ECG, and sometimes MRI. After the PET scan, blood samples will be collected, and a follow-up phone call will check for any side effects. Researchers will measure brain uptake of the tracer, monitor vital signs, and track any adverse events to assess safety and imaging accuracy.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the early brain regions involved in Alzheimers disease and its precursors using novel molecular probes 18FAV45 Ab2 and 18FAV1451 Tau with PETCT imaging. This study aims to understand the distribution of positive brain lesions affecting mental state tests like the simple mental state examination and the Montreal Cognitive Assessment Scale in Alzheimers patients. The goal is to provide molecular imaging information that may help study Alzheimers disease mechanisms and establish objective diagnostic criteria for early detection. The study uses new imaging agents Ab2 and Tau PETCT, which can detect pathological changes at the molecular level before symptoms appear. These molecular probes offer earlier and more visual detection of Alzheimers disease-related changes, helping to define positive diagnostic criteria for early Alzheimers disease. Participants include groups with mild cognitive impairment, Alzheimers disease, and healthy volunteers. Participants will be assessed through PETCT imaging using these molecular probes to observe brain pathology. Researchers will evaluate the diagnostic criteria for Ab2 and Tau imaging within two months. The study includes cognitive tests and clinical dementia rating scales. This observational study involves healthy volunteers and patients with mild cognitive impairment or Alzheimers disease, aiming to improve early diagnosis through imaging techniques.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and diagnostic effectiveness of 18FFT8 PET imaging for detecting AL amyloidosis, focusing on its ability to directly visualize amyloid deposits in heart tissue. The study compares this new imaging approach with established methods such as echocardiography, contrast-enhanced MRI, and various laboratory tests to better differentiate AL amyloidosis from other conditions. Participants will receive a single intravenous injection of 10 3 mCi of 18FFT8, followed by a PETCT scan to assess organ uptake using standardized uptake values SUV. The study includes both patients with suspected or diagnosed cardiac amyloidosis and healthy volunteers. Clinical assessments and laboratory tests, including physical exams and evaluations of cardiac, liver, and kidney function, will be done before and after the scan to monitor safety and biodistribution. During the study, participants will undergo a single PETCT scan session and related clinical evaluations. Researchers will monitor safety from the time of injection up to seven days afterward and analyze the radiation dosage and biodistribution of 18FFT8. The total participation involves initial assessments, the scan, and follow-up safety monitoring, with data collected primarily on the imaging results and participant well-being.
Actively Recruiting
Healthy Volunteer
Researchers are studying a new imaging tracer called 18FNIDF to detect abnormal tau protein buildup in the brains of people with neurodegenerative diseases, including Alzheimers disease and related tauopathies. This study focuses on evaluating the safety and diagnostic ability of 18FNIDF PET imaging in living human brains, aiming to improve visualization of tau pathology compared to existing tracers. The research is sponsored by Tianjin Medical University. Participants receive a single intravenous injection of about 10 3 mCi of 18FNIDF, followed by a PETCT scan to track the tracers distribution in the brain. The study includes both healthy volunteers and patients with cognitive impairments, such as probable Alzheimers disease or other dementias. The imaging is done once, and safety is monitored up to 7 days after injection. During the study, participants will be observed for any side effects and undergo a PETCT scan to assess how well the tracer binds to tau proteins. Researchers will measure safety from the time of injection up to one week later and evaluate the diagnostic performance within two weeks of scanning. The total participation period includes the imaging day and follow-up safety assessments, with the study running until December 2030.
Actively Recruiting
Researchers are evaluating the use of PET imaging with the radioligand 18FPI-2620 to detect tau protein buildup in people with Alzheimers disease and control subjects. This open-label, multi-center, pivotal Phase 3 study compares imaging results during life to brain tissue analysis after death to assess the accuracy and safety of this diagnostic method. Participants will receive an intravenous injection of 18FPI-2620 at a dose of 185 MBq 20%. This study is non-randomized and single-group, focusing on the imaging procedure itself without placebo or alternative treatments. The study will continue until autopsy and brain tissue analysis are completed, with an average follow-up period of about one year. During the study, participants will undergo PET scans using 18FPI-2620. Researchers will assess the scans ability to correctly identify tau pathology related to Alzheimers disease by comparing them to post-mortem brain tissue analysis. The study includes safety monitoring and evaluation of the agreement between different readers interpreting the scans. Overall participation lasts until the participants death and brain autopsy, expected on average around one year after the scan.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a multicenter phase III clinical trial to assess how well PET scans using 18FFluorbetazine injection can detect amyloid beta A plaques in the brains of people with normal cognitive function, mild cognitive impairment MCI caused by Alzheimers disease AD, and AD dementia. The study aims to evaluate the diagnostic accuracy and safety of this imaging method for these groups. Participants receive a single intravenous injection of 18FFluorbetazine followed by PET imaging to visualize A plaque deposition. The study focuses on measuring sensitivity and specificity of the PET images compared to established standards. Researchers also analyze brain uptake patterns and image consistency among readers during the one-year follow-up period. During the trial, participants undergo PET scans and brain MRIs to assess plaque accumulation and brain structure. Researchers collect imaging data including standardized uptake value ratios and gray-to-white matter ratios. The primary outcome measures how accurately PET imaging identifies amyloid plaques. Safety and tolerability of the injection are also monitored throughout the study, which lasts up to one year from imaging.
Actively Recruiting
Researchers are evaluating the Green Activity Program designed for people living with memory challenges and their study partners. The program includes outdoor nature activities such as dog walking, hiking, yoga, and gardening, aiming to help participants stay active and improve their health and well-being. This feasibility study focuses on whether participants can complete and enjoy the program, supporting their participation in nature activities. The study involves a single group of 40 pairs dyads consisting of individuals with memory challenges and their study partners. Over 12 weeks, participants engage in 4 to 8 virtual or phone sessions lasting 30 to 90 minutes each, plus 2 additional check-ins of 15 to 30 minutes. Outdoor activity professionals also participate by evaluating sites for safety and accessibility, receiving dementia training, and learning strategies to tailor activities and provide behavioral support. Participants complete evaluations before and after the 12-week program, including surveys, brief phone interviews, and physical activity and health assessments. Researchers measure feasibility, acceptability, behavior change, physical activity, well-being, social participation, depression, cognitive function, and other health-related outcomes. Feedback from study partners and outdoor professionals is also collected. The total study duration for participants may last up to one year to include all evaluations and follow-ups.
Actively Recruiting
Researchers are evaluating the safety of LY3954068 in adults aged 50 to 85 with early symptomatic Alzheimers Disease. This Phase 1 study also investigates how much LY3954068 enters the bloodstream and examines its effects on Alzheimers disease markers. The study is divided into two parts to assess different dosing strategies. In Part A, each participant receives a single dose of LY3954068 or placebo injected into the spinal fluid. In Part B, participants may receive up to four doses of LY3954068 or placebo administered the same way. There is also an optional bridging period where participants might receive LY3954068 in a separate study. The study lasts about 45 weeks for Part A and up to 100 weeks for Part B, including screening. Participants will undergo various assessments such as spinal fluid sampling, blood tests, and PET scans using Flortaucipir F18 to observe tau protein changes. Safety is monitored by tracking adverse events related to the study drug. Cognitive tests like the Mini Mental State Examination and Clinical Dementia Rating are used to evaluate memory and dementia severity. Regular visits occur throughout the study to collect data, monitor health, and assess treatment effects.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the relationship between gut microbiota dysfunction and Alzheimers disease AD, focusing on how gut-derived short-chain fatty acids SCFAs may influence brain function through the gut microbiota-SCFAs-brain networks pathway. This observational study will explore differences in SCFAs among people across the AD spectrum, including cognitively normal individuals, those with subjective cognitive decline SCD, mild cognitive impairment MCI, and AD dementia. The project aims to clarify the interactions between gut microbiome, metabolites, and brain changes using high-throughput metabolomics and multi-modal MRI techniques. Participants will be grouped into four categories cognitively normal, SCD, MCI, and AD dementia. The study involves collecting multi-omics data, including gut microbiome analysis, metabolomics, and neuroimaging, to establish a diagnostic model for SCD due to preclinical AD using machine learning methods. The study spans five years, during which gut microbiome changes, SCFAs levels, and multi-omics biomarkers related to cognitive impairment conversion will be monitored. Participants will undergo cognitive tests and brain imaging scans, along with gut microbiome and metabolite sample collection. Researchers will assess the interaction mechanisms of the gut microbiota-SCFAs-brain networks over five years. The study includes both healthy volunteers and patients aged 60 to 80. Outcome measures focus on changes in gut microbiome, SCFAs, and biomarkers linked to cognitive decline, with long-term follow-up to better understand the disease progression and its early detection.
1-10 of 488
1